Drugs of abuse and brain gene expression

Psychosomatic Medicine

Volumn 61, Issue 5, 1999, Pages 630-650

  Torres, German ^a   Horowitz, Judith M ^b  

^a UNIVERSITY AT BUFFALO   (United States)

^b MEDAILLE COLLEGE   (United States)

Author keywords

Addiction; Dopamine; Genes; Mutagenesis; Rodents; Striatum

Indexed keywords

ALCOHOL; COCAINE; MORPHINE; TRANSCRIPTION FACTOR;

ARTICLE; DRUG DEPENDENCE; DRUG STRUCTURE; GENE EXPRESSION REGULATION; HUMAN; MUTAGENESIS; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

EID: 0032878860     PISSN: 00333174     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006842-199909000-00007     Document Type: Article

References (213)

1. Leshner AI. Addiction is a brain disease, and it matters. Science 1997;278:45-7.
2. Koob GF. Drug addiction: the yin and yang of hedonic homeostasis. Neuron 1996;16:893-6.
3. Genova L, Berke J, Hyman SE. Molecular adaptations to psychostimulants in striatal neurons: toward a pathophysiology of addiction. Neurobiol Dis 1997;4:239-46.
4. Nestler EJ. Molecular mechanisms of drug addiction. J Neurosci 1992;12:2439-50.
5. Torres G, Horowitz JM. Individual and combined effects of ethanol and cocaine on intracellular signals and gene expression. Prog Neuropsychopharmacol Biol Psychiatry 1996;20: 561-96.
6. Gawin FH. Cocaine addiction: psychology and neurophysiology. Science 1991;251:1580-6.
7. Sheng M, Greenberg ME. The regulation and function of c-fos and other immediate early genes in the nervous system. Neuron 1990;4:477-85.
8. Morgan JI, Curran T. Immediate-early genes: ten years on. Trends Neurosci 1995;2:66-7.
9. Hyman SE. Addiction to cocaine and amphetamine. Neuron 1996;16:901-4.
10. Franza BR Jr, Rauscher FJ III, Josephs SF, Curran T. The Fos complex and Fos-related antigens recognize sequence elements that contain AP-1 binding sites. Science 1988;239:1150-3.
11. Rauscher FJ III, Voulalas PJ, Franza BR Jr, Curran T. Fos and Jun bind cooperatively to the AP-1 sites: reconstitution in vitro. Genes Dev 1988;2:1687-99.
12. Ayoubi TAY, van de Ven WJM. Regulation of gene expression by alternative promoters. FASEB J 1996;10:453-60.
13. Hunter T, Karin M. The regulation of transcription by phosphorylation. Cell 1992;70:375-87.
14. Montminy MR, Gonzalez GA, Yamamoto KK. Regulation of cAMP-inducible genes by CREB. Trends Neurosci 1990;13: 184-8.
15. Karin M, Smeal T. Control of transcription factors by signal transduction pathways: the beginning of the end. Trends Biol Sci 1992;17:418-22.
16. Koob GF. Drugs of abuse: anatomy, pharmacology and function of reward pathways. Trends Pharmacol Sci 1992;22:575-81.
17. Schultz W. Dopamine neurons and their role in reward mechanisms. Curr Opin Neurobiol 1997;7:191-7.
18. Horowitz JM, Torres G. Cocaethylene: effects on brain systems and behavior. Addiction Biol 1999;4:127-40.
19. Hermanson O, Hallbeck M, Blomqvist A. Preproenkephalin mRNA-expressing neurones in the rat thalamus. Neuroreport 1995;6:833-6.
20. Nestler EJ. Under siege: the brain on opiates. Neuron 1996;16: 897-900.
21. Mansour A, Fox CA, Burke S, Meng F, Thompson, RC, Akil H, Watson SJ. Mu, delta, and kappa opioid receptor mRNA expression in the rat CNS: an in situ hybridization study. J Comp Nuerol 1994;350:412-38.
22. Mansour A, Hoversten MT, Taylor LP, Watson SJ, Akil H. The cloned mu, delta and kappa receptors and their endogenous ligands: evidence for two opioid peptide recognition cores. Brain Res 1995;700:89-98.
23. Meunier J-C, Mollereau C, Toll L, Suaudeau C, Moisand C, Alvinerie P, Butoor JL, Guillemot JC, Ferrara P, Monsarrat B. Isolation and structure of the endogenous agonists of opioid receptor-like ORL1 receptor. Nature 1995;377:532-5.
24. Zadina JE, Hackler L, Ge L-J, Kastin AJ. A potent and selective endogenous agonist for the μ-opiate receptor. Nature 1997;386: 499-501.
25. Okuda-Ashitaka E, Minami T, Tachibana S, Yoshihara Y, Nishiuchi Y, Kimura T, Ita S. Nocistatin, a peptide that blocks nociceptin action in pain transmission. Nature 1997;392: 286-9.
26. 1 dopamine receptor-mediated immediate-early gene expression in the striatum. J Comp Neurol 1995;353: 200-12.
27. LeMoine C, Normand E, Guitteny AF, Fouque B, Teoule R, Bloch B. Dopamine receptor gene expression by enkephalin neurons in rat forebrain. Proc Natl Acad Sci USA 1990;87: 230-4.
28. Surmeier DJ, Eberwine J, Wilson CJ, Cao Y, Stefani A, Kitai ST. Dopamine receptor subtypes colocalize in rat striatonigral neurons. Proc Natl Acad Sci USA 1992;89:10178-82.
29. Cole RL, Konradi C, Douglass J, Hyman SE. Neuronal adaptation to amphetamine and dopamine: molecular mechanisms of prodynorphin gene regulation in rat striatum. Neuron 1995;14: 813-23.
30. 2 dopamine receptor-regulated gene expression of strianigral and striatopallidal neurons. Science 1990;250:1429-32.
31. 1 dopamine receptor gene. Proc Natl Acad Sci USA 1991;88:4205-9.
32. Hanson GR, Merchant KM, Letter AA, Bush L, Gibb JW. Characterization of methamphetamine effects on the striatal-nigral dynorphin system. Eur J Pharmacol 1988;155:11-8.
33. Hurd YL, Herkenham M. Influence of a single injection of cocaine, amphetamine of GBR 12909 on mRNA expression of striatal neuropeptides. Mol Brain Res 1992;16:97-104.
34. 1 and N-methyl-D-aspartate receptors. Proc Natl Acad Sci USA 1994;91:8537-41.
35. Bot G, Chahl LA. Induction of Fos-like immunoreactivity by opioids in guinea-pig brain. Brain Res 1996;731:45-56.
36. Mody I, DeKoninck Y, Otis TS, Soltesz I. Bridging the cleft at GABA synapses in the brain. Trends Neurosci 1994;17:517-25.
37. Franks NP, Lieb WR. Molecular and cellular mechanisms of general anaesthesia. Nature 1994;367:607-14.
38. 1 receptor GABAergic currents by alcohols and volatile anesthetics. J Pharmacol Exp Ther 1996;277:411-6.
39. Mihic SJ, Ye Q, Wick MJ, Koltchine W, Krasowski MD, Finn SE, Mascia MP, Valenzuela CF, Hanson KK, Greenblatt EP, Harris RA, Harrison NL. Sites of alcohol and volatile anaesthesic action in GABA(A) and glycine receptors. Nature 1997;389: 385-9.
40. Burt DR, Kamatchi GL. GABAA receptor subtypes: from pharmacology to molecular biology. FASEB J 1991;5:2916-23.
41. Nevo I, Hamon M. Neurotransmitter and neuromodulatory mechanisms involved in alcohol abuse and alcoholism. Neurochem Int 1995;26:305-36.
42. Diamond I, Gordon AS. Cellular and molecular neuroscience of alcoholism. Physiol Rev 1997;77:1-20.
43. Cameron DL, Williams JT. Cocaine inhibits GABA release in the VTA through endogenous 5-HT. J Neurosci 1994;14: 6763-7.
44. Kawaguchi Y, Kubota Y. Functions of cortico-basal ganglia loop. In: Kimura M, Graybiel AM, editors. New York: Springer-Verlag; 1995.
45. Somers DL, Beckstead RM. N-methyl-D-aspartate receptor antagonism alters substance P and met-enkephalin biosynthesis in neurons of the rat striatum. J Pharmacol Exp Ther 1992;262: 823-33.
46. Cadet JL, Bolla KI. Chronic cocaine use as a neuropsychiatric syndrome: a model for debate. Synapse 1996;22:28-34.
47. Hurd YL, Herkenham M. Molecular alterations in the neostriatum of human cocaine addicts. Synapse 1993;13:357-69.
48. Kuhar MJ, Pilotte NS. Neurochemical changes in cocaine withdrawal. Trends Pharmacol Sci 1996;17:260-4.
49. Amara SG. Monoamine transporters: basic biology with clinical implications. Neuroscientist 1995;1:259-67.
50. Giros B, Jaber M, Jones SR, Wightman RM, Caron MG. Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter. Nature 1996;279: 606-12.
51. Jones SR, Gainetdinov RR, Jaber M, Giros B, Wightman RM, Caron MG. Profound neuronal plasticity in response to inactivation of the dopamine transporter. Proc Natl Acad Sci USA 1998;95:4029-34.
52. Shimada S, Kitayama S, Lin CL, Patel A, Nanthakumar E, Gregor P, Kuhar M, Uhl G. Cloning and expression of a cocaine-sensitive dopamine transporter complementary DNA. Science 1991;254:576-8.
53. Kilty JE, Lorang D, Amara SG. Cloning and expression of a cocaine-sensitive rat dopamine transporter. Science 1991;254: 578-9.
54. Kuhar MJ, Ritz MC, Boja JW. The dopamine hypothesis of the reinforcing properties of cocaine. Trends Neurosci 1991;14: 299-302.
55. Graybiel AM, Moratalla R, Robertson HA. Amphetamine and cocaine induce drug-specific activation of the c-fos gene in striosome-matrix compartments and limbic subdivisions of the striatum. Proc Natl Acad Sci USA 1990;87:6912-6.
56. 1 receptors. Proc Natl Acad Sci USA 1991;88:1291-5.
57. Moratalla R, Robertson HA, Graybiel AM. Dynamic regulation of NGFI-A (zif268, erg1) gene expression in the striatum. J Neurosci 1992;12:2609-22.
58. Torres G, Rivier C. Differential effects of intermittent or continuous exposure to cocaine on the hypothalamic-pituitary-adrenal axis and c-fos expression. Brain Res 1992;571:204-11.
59. Bhat RV, Baraban JM. Activation of transcription factor genes in striatum by cocaine: role of both serotonin and dopamine systems. J Pharmacol Exp Ther 1993;267:496-504.
60. Klitenick MA, Tham C-S, Fibiger HC. Cocaine and d-amphetamine increase c-fos expression in the rat cerebellum. Synapse 1995;19:29-36.
61. Berretta S, Robertson HA, Graybiel AM. Dopamine and glutamate agonists stimulate neuron-specific expression of Fos-like protein in the striatum. J Neurophysiol 1992;68:767-77.
62. Torres G, Rivier C. Cocaine-induced expression of striatal c-fos in the rat is inhibited by NMDA receptor antagonists. Brain Res Bull 1993;30:173-6.
63. Couceyro P, Pollock KM, Drews K, Douglass J. Cocaine differentially regulates activator protein-1 mRNA levels and DNA-binding complexes in the rat striatum and cerebellum. Mol Pharmacol 1994;46:667-76.
64. Bhat RV, Cole AJ, Baraban JM. Chronic cocaine treatment suppresses basal expression of zif268 in rat forebrain: in situ hybridization studies. J Pharmacol Exp Ther 1992;263:343-9.
65. 1B/1D antagonist GR127935. Mol Pharmacol 1997;51:755-63.
66. Boschert U, Ait Amara D, Segu L, Hen R. The mouse 5-hydroxytryptamine 1B receptor is localized predominantly on axon terminals. Neuroscience 1993;58:167-82.
67. 1B binding sites in the rat brain. Naunyn Schmiedebergs Arch Pharmacol 1993;347:569-82.
68. Gerfen CR. The neostriatal mosaic: multiple levels of compartmental organization in the basal ganglia. Trends Neurosci 1992;15:133-9.
69. Kawaguchi Y, Wilson CJ, Augood SJ, Emson PC. Striatal interneurons: chemical, physiological and morphological characterization. Trends Neurosci 1995;18:527-35.
70. Surmeier DL, Song WJ, Van Z. Coordinated expression of dopamine receptors in neostriatal medium spiny neurons. J Neurosci 1996;16:6579-91.
71. Kita H. GABAergic circuits of the striatum. Prog Brain Res 1993;99:51-72.
72. Cenci MA, Campbell K, Wictorin K, Bjorklund A. Striatal c-fos induction by cocaine or apomorphine occurs preferentially in output neurons projecting to the substantia nigra in the rat. Eur J Neurosci 1992;4:376-80.
73. Steiner H, Gerfen CR. Cocaine-induced c-fos messenger RNA is inversely related to dynorphin expression in striatum. J Neurosci 1993;13:5066-81.
74. Moratalla R, Vickers EA, Robertson HA, Cochran BH, Graybiel AM. Coordinate expression of c-fos and jun B is induced in the rat striatum by cocaine. J Neurosci 1993;13:423-33.
75. Hope B, Kosofsky B, Hyman SE, Nestler EJ. Regulation of immediate-early gene expression and AP-1 binding in the rat nucleus accumbens by chronic cocaine. Proc Natl Acad Sci USA 1992;89:5764-8.
76. Hope BT, Nye HE, Kelz MB, Self DW, Iadarola MJ, Nakabeppu Y, Duman RS, Nestler EJ. Induction of a long-lasting AP-1 complex composed of altered Fos-like proteins in brain by chronic cocaine and other chronic treatments. Neuron 1994; 13:1235-44.
77. Rosen JB, Chuang E, Iadarola MJ. Differential induction of Fos protein and a Fos-related antigen following acute and repeated cocaine administration. Mol Brain Res 1994;25:168-72.
78. 1-Class dopamine receptors influence cocaine-induced persistent expression of Fos-related proteins in striatum. Neuroreport 1996;8: 1-5.
79. Moratalla R, Elibol B, Vallejo M, Graybiel AM. Network-level changes in expression of inducible Fos-Jun proteins in the striatum during chronic cocaine treatment and withdrawal. Neuron 1996;17:147-56.
80. Mumberg D, Lucibello FC, Schuermann M, Muller R. Alternative splicing of fosB transcripts results in differentially expressed mRNAs encoding functionally antagonistic proteins. Genes Dev 1991;5:1212-23.
81. Nakabeppu Y, Nathans D. A naturally occurring truncated form of FosB that inhibits Fos/Jun transcriptional activity. Cell 1991; 64:751-9.
82. Yen J, Wisdom RM, Tratner I, Verma IM. An alternative spliced form of FosB is a negative regulator of transcriptional activation and transformation by Fos proteins. Proc Natl Acad Sci USA 1991;88:5077-81.
83. Herschman HR. Primary response genes induced by growth factors and tumor promoters. Ann Rev Biochem 1991;60: 281-319.
84. Hiroi N, Brown J, Haile CH, Ye H, Greenberg ME, Nestler EJ. FosB mutant mice: loss of chronic cocaine induction of Fos-related proteins and heightened sensitivity to cocaine's psychomotor and rewarding effects. Proc Natl Acad Sci USA 1997; 94:10397-402.
85. Wahlestedt C, Kauoum F, Jaskiw G, Wyatt RJ, Larhammar D, Ekman R, Reis DJ. Cocaine-induced reduction of brain neuropeptide Y synthesis dependent on medial prefrontal cortex. Proc Natl Acad Sci USA 1991;88:2078-82.
86. Smiley PL, Johnson M, Bush L, Gibb JW, Hanson GR. Effects of cocaine on extrapyramidal and limbic dynorphin systems. J Pharmacol Exp Ther 1990;253:938-43.
87. Daunais JB, McGinty JF. Cocaine binges differentially alter striatal preprodynorphin and zif/268 mRNAs. Mol Brain Res 1995;29:201-10.
88. Fosnaugh JS, Bhat RV, Yamagata K, Worley PF, Baraban JM. Activation of arc, a putative "effector" immediate early gene, by cocaine in rat brain. J Neurochem 1995;64:2377-80.
89. Lyford GL, Yamagata K, Kaufmann WE, Barnes CA, Sanders LK, Copeland NG, Gilbert DJ, Jenkins NA, Lanahan AA, Worley PF. Arc, a growth factor and activity-regulated gene, encodes a novel cytoskeleton-associated protein that is enriched in neuronal dendrites. Neuron 1995;14:433-45.
90. Nestler EJ, Hope BT, Widnell KL. Drug addiction: a model for the molecular basis of neural plasticity. Neuron 1993;11: 995-1006.
91. Douglass J, McKinzie AA, Couceyro P. PCR differential display identifies a rat brain mRNA that is transcriptionally regulated by cocaine and amphetamine. J Neurosci 1995;15:2471-81.
92. Douglass J, Daoud R. Characterization of the human cDNA and genomic DNA encoding CART: a cocaine- and amphetamine-regulated transcript. Gene 1996;169:241-5.
93. Smith Y, Koylu EO, Couceyro P, Kuhar MJ. Ultrastructural localization of CART (cocaine- and amphetamine-regulated transcript) peptides in the nucleus accumbens of monkeys. Synapse 1997;27:90-4.
94. Koylu EO, Couceyro PR, Lambert PD, Kuhar MJ. Cocaine- and amphetamine-regulated transcript peptide immunohistochemical localization in the rat brain. J Comp Neurol 1998;391: 115-32.
95. Couceyro PR, Koylu EO, Kuhar MJ. Further studies on the anatomical distribution of CART by in situ hybridization. J Chem Neuroanat 1997;12:229-41.
96. Cha X-Y, Pierce RC, Kalivas PW, Mackler SA. NAC-1, a rat brain mRNA, is increased in the nucleus accumbens three weeks after chronic cocaine self-administration. J Neurosci 1997;17:6864-71.
97. Cerruti C, Pilotte NS, Uhl G, Kuhar MJ. Reduction in the dopamine transporter mRNA after cessation of repeated cocaine administration. Mol Brain Res 1994;22:132-8.
98. Berhow MT, Hiroi N, Kobierski LA, Hyman SE, Nestler EJ. Influence of cocaine on the JAK-STAT pathway in the mesolimbic dopamine system. J Neurosci 1996;16:8019-26.
99. Mathey-Prevot B, Perrimon N. Mammalian and Drosophila blood: JAK of all trades? Cell 1998;92:697-700.
100. Rivier C, Lee S. Stimulatory effect of cocaine on ACTH secretion: role of the hypothalamus. Mol Cell Neurosci 1994; 5:189-95.
101. Zhou Y, Spangler R, LaForge KS, Maggos CE, Ho A, Kreek MJ. Corticotropin-releasing factor and type-1 corticotropin-releasing factor receptor messenger RNAs in rat brain and pituitary during "binge"-pattern cocaine administration and chronic withdrawal. J Pharmacol Exp Ther 1996;279:351-8.
102. Piazza PV, LeMoal M. Glucocorticoids as a biological substrate of reward: physiological and pathophysiological implications. Brain Res Rev 1997;25:359-72.
103. Piazza PV, LeMoal M. The role of stress in drug self-administration. Trends Pharmacol Sci 1998;19:67-74.
104. Lobe CG, Nagy A. Conditional genome alteration in mice. Bioessays 1998;20:200-8.
105. Reeves RG. Exploring development and disease through germline genetic engineering in the mouse. Anat Rec 1998;253: 19-23.
106. Gerlai R. Gene-targeting studies of mammalian behavior: is it the mutation or the background genotype? Trends Neurosci 1996;19:177-86.
107. Crawley JN, Belknap JK, Collins A, Crabbe JC, Frankel W, Henderson N, Hitzemann RJ, Maxson SC, Miner LL, Silva AJ, Wehner JM, Wynshaw-Boris A, Paylor R. Behavioral phenotypes of inbred mouse strains: implications and recommendations for molecular studies. Psychopharmacology 1997;132: 107-24.
108. Rocha BA, Fumagalli F, Gainetdinov RR, Jones S, Ator R, Giros B, Miller GW, Caron MG. Cocaine self-administration in dopamine-transporter knockout mice. Nature Neurosci 1998;1: 132-7.
109. Sora I, Wichems C, Takahashi N, Li X-F, Zeng Z, Revay R, Lesch K-P, Murphy DL, Uhl GR. Cocaine reward models: conditioned place preference can be established in dopamine- and in serotonin-transporter knockout mice. Proc Natl Acad Sci USA 1998;95:7699-704.
110. Rocha BA, Scearce-Levie K, Lucas JJ, Hiroi N, Castanon N, Crabbe JC, Nestler EJ, Hen R. Increased vulnerability to cocaine in mice lacking the serotonin-1B receptor. Nature 1998;393: 175-7.
111. 1 dopamine receptor-deficient mouse: cocaine-induced regulation of immediate-early gene and substance P expression in the striatum. Neuroscience 1996;74:813-23.
112. 2 knockout mice: heterozygotes display reduced amphetamine-conditioned reward, enhanced amphetamine locomotion, and enhanced MPTP toxicity. Proc Natl Acad Sci USA 1997;94: 9938-43.
113. Wang Y-M, Gainetdinov RR, Fumagalli F, Xu F, Jones SR, Bock CB, Miller GW, Wightman RM, Caron MG. Knockout of the vesicular monoamine transporter 2 gene results in neonatal death and supersensitivity to cocaine and amphetamine. Neuron 19997;19:1285-96.
114. Chambon P. A decade of molecular biology of retinoic acid receptors. FASEB J 1996;10:940-54.
115. Krezel W, Ghyselinck N, Samad TA, Dupe V, Kastner P, Borrelli E, Chambon P. Impaired locomotion and dopamine signaling in retinoid receptor mutant mice. Science 1998;279: 863-7.
116. Missale C, Nash SR, Robinson SW, Jaber M, Caron MG. Dopamine receptors: from structure to function. Physiol Rev 1998; 78:189-225.
117. 3 dopamine receptors in the brain reward circuits of human cocaine fatalities. J Neurosci 1996;16:6100-6.
118. Seeman P. Dopamine receptors and psychosis. Sci Am Sci Med 1995;5:28-37.
119. 2 receptors. Neuron 1997;19:837-48.
120. 4 receptors are supersensitive to ethanol, cocaine, and methamphetamine. Cell 1997;90:991-1001.
121. Diamond I, Messing RO. Neurologic effects of alcoholism. West J Med 1994;161:279-87.
122. Zakhari S. Alcohol and the cardiovascular system. Alcohol Health Res World 1997;21:21-9.
123. Yoshimoto K, McBride WJ, Lumeng L, Li TK. Ethanol enhances the release of dopamine and serotonin in the nucleus accumbens of HAD and LAD lines of rats. Alcohol Clin Exp Res 1992;16:781-5.
124. DiChiara G. Alcohol and dopamine. Alcohol World Alcohol Res 1997;21:108-13.
125. Lovinger DM. Serotonin's role in alcohol's effects on the brain. Alcohol World Alcohol Res 1997;21:114-9.
126. Samson HH, Harris RA. Neurobiology of alcohol abuse. Trends Pharmacol Sci 1992;13:206-11.
127. Tabakoff B, Hoffman PL. Alcohol addiction: an enigma among us. Neuron 1996;16:909-12.
128. Buck KJ. Molecular genetic analysis of the role of GABAergic systems in the behavioral and cellular actions of alcohol. Behav Genet 1996;26:313-21.
129. Rivier C. Alcohol stimulates ACTH secretion in the rat: mechanisis of action and interactions with other stimuli. Alcohol Clin Exp Res 1996;20:240-54.
130. Lee S, Rivier C. An initial, three-day-long treatment with alcohol induces a long-lasting phenomenon of selective tolerance in the activity of the rat hypothalamic-pituitary-adrenal axis. J Neurosci 1997;17:8856-66.
131. Angelogianni P, Gianoulakis C. Chronic ethanol increases pro-opiomelanocortin gene expression in the rat hypothalamus. Neuroendocrinology 1993;57:106-14.
132. Gulya K, Orpana AK, Sikela JM, Hoffman PL. Prodynorphin and vasopressin mRNA levels are differentially affected by chronic ethanol ingestion in the mouse. Mol Brain Res 1993; 20:1-8.
133. 1 receptor subunit immunoreactivity in rat hippocampus. J Neurochem 1994;62:1635-8.
134. Fitzgerald LW, Charlton ME, Duman RS, Nestler EJ. Regulation of neuronal nitric oxide synthase by chronic ethanol ingestion. Synapse 1995;21:93-5.
135. Ortiz J, Fitzgerald LW, Charlton M, Lane S, Trevisan L, Guitart X, Shoemaker W, Duman RS, Nestler EJ. Biochemical actions of chronic ethanol exposure in the mesolimbic dopamine system. Synapse 1995;21:289-98.
136. Tabakoff B, Whelan JP, Ovchinnikova L, Nhamburo P, Yoshimura M, Hoffman PL. Quantitative changes in G proteins do not mediate ethanol-induced downregulation of adenylyl cyclase in mouse cerebral cortex. Alcohol Clin Exp Res 1995;19: 187-94.
137. Yang X, Horn K, Wand GS. Chronic ethanol exposure impairs phosphorylation of CREB and CRE-binding activity in rat striatum. Alcohol Clin Exp Res 1998;22:382-90.
138. Gianoulakis C. Endogenous opioids and excessive alcohol consumption. J Psychiatr Neurosci 1993;18:148-56.
139. Froehlich JC. Opioid peptides. Alcohol World Health Res 1997; 21:132-5.
140. Spanagel R, Zieglgänsberger W. Anti-craving compounds for ethanol: new pharmacological tools to study addictive processes. Trends Pharmacol Sci 1997;18:54-9.
141. Le F, Wilce PA, Cassady I, Hume DA, Shanley BC. Acute administration of ethanol suppresses pentylenetetrazole-induced c-fos expression in rat brain. Neurosci Lett 1990;120: 271-4.
142. Le F, Wilce PA, Hume DA, Shanley BC. Involvement of gamma-aminobutyric acid and N-methyl-D-aspartate receptors in the inhibitory effects of ethanol on pentylenetetrazole-induced c-fos expression in rat brain. J Neurochem 1992;59:1309-15.
143. Torres G. Acute administration of alcohol blocks cocaine-induced striatal c-fos immunoreactivity protein in the rat. Synapse 1994;18:161-7.
144. Lee S, Rivier C. Interaction between alcohol and interleukin-1β on ACTH secretion and the expression of immediate early genes in the hypothalamus. Mol Cell Neurosci 1994;5:442-50.
145. Ryabinin AE, Melia KR, Cole M, Bloom FE, Wilson MC. Alcohol selectively attenuates stress-induced c-fos expression in rat hippocampus. J Neurosci 1995;15:721-30.
146. Torres G, Horowitz JM. Combined effects of ethanol and cocaine on FOS-like protein and cocaethylene biosynthesis in the rat. Psychopharmacology (Berl) 1996;128:105-14.
147. Ryabinin AE, Criado JR, Henriksen SJ, Bloom FE, Wilson MC. Differential sensitivity of c-fos expression in hippocampus and other brain regions to moderate and low doses of alcohol. Mol Psychiatry 1997;2:32-43.
148. Zoeller RT, Fletcher DL. A single administration of ethanol simultaneously increases c-fos mRNA and reduces c-jun mRNA in the hypothalamus and hippocampus. Mol Brain Res 1994;24:185-91.
149. Chang SL, Patel NA, Romero AA. Activation and desensitization of Fos immunoreactivity in the rat brain following ethanol administration. Brain Res 1995;679:89-98.
150. Thiele TE, van Dijk G, Bernstein IL. Ethanol-induced c-Fos expression in rat lines selected for low and high alcohol consumption. Brain Res 1997;756:278-82.
151. Lovinger DM, White G, Weight F. Ethanol inhibits NMDA-activated ion currents in hippocampal neurons. Science 1989; 243:1721-3.
152. Dean RA, Christian CD, Sample RHB, Bosron WF. Human liver cocaine esterases: ethanol-mediated formation of ethylcocaine. FASEB J 1991;5:2735-9.
153. Hearn WL, Flynn DD, Hime GW, Rose S, Cofino JC, Mantero-Atienza E, Wetli CV, Mash DC. Cocaethylene: a unique cocaine metabolite displays high affinity for the dopamine transporter. J Neurochem 1991;56:698-701.
154. McCance EF, Price LH, Kosten TR, Jatlow PI. Cocaethylene: pharmacology, physiology and behavioral effects in humans. J Pharmacol Exp Ther 1995;274:215-23.
155. Horowitz JM, Bhatti E, Devi BG, Torres G. Behavior and drug measurements in Long-Evans and Sprague-Dawley rats after ethanol-cocaine exposure. Pharmacol Biochem Behav 1999;62: 329-37.
156. Bradberry CW, Nobiletti JB, Elsworth JD, Murphy B, Jatlow P, Roth RH. Cocaine and cocaethylene: microdialysis comparison of brain drug levels and effects on dopamine and serotonin. J Neurochem 1993;60:1429-35.
157. Iyer RN, Nobiletti JB, Jatlow PI, Bradberry CW. Cocaine and cocaethylene: effects on extracellular dopamine in the primate. Psychopharmacology 1995;120:140-55.
158. Horowitz JM, DiPirro JM, Kristal MB, Torres G. Dopaminergic and glutamatergic mechanisms mediate the induction of FOS-like protein by cocaethylene. Brain Res Bull 1997;42:393-8.
159. Torres G, Horowitz JM, Lee S, Rivier C. Cocaethylene stimulates the secretion of ACTH and corticosterone and the transcriptional activation of hypothalamic NGFI-β. Mol Brain Res 1996;43:225-32.
160. Haber H, Roske I, Rottman M, Georgi M, Melzig MF. Alcohol induces formation of morphine precursors in the striatum of rats. Life Sci 1997;60:79-89.
161. Myers RD, Melchior CL. Alcohol drinking: abnormal intake caused by tetrahydropapaveroline in brain. Science 1977;196: 554-6.
162. Myers RD, McCalbe ML, Ruwe WD. Alcohol drinking induced in the monkey by tetrahydropapaveroline (THP) infused into the cerebral ventricle. Pharmacol Biochem Behav 1982;16: 995-1000.
163. 2 receptor genes. Trends Neurosci 1993;16:83-8.
164. Noble EP. The gene that rewards alcoholism. Sci Am Sci Med 1996;3:52-61.
165. 2 receptor gene: a genetic risk factor in substance abuse. Drug Alcohol Depend 1994;34:175-80.
166. Buck KJ. Strategies for mapping and identifying quantitative trait loci specifying behavioral responses to alcohol. Alcohol Clin Exp Res 1995;19:795-801.
167. Buck KJ, Metten P, Belknap JK, Crabbe JC. Quantitative trait loci involved in genetic predisposition to acute alcohol withdrawal in mice. J Neurosci 1997;17:3946-55.
168. Puglisi-Allegra S, Cabib S. Psychopharmacology of dopamine: the contribution of comparative studies in inbred strains of mice. Prog Neurobiol 1997;51:637-61.
169. LeMarquand D, Pihl RO, Benkelfat C. Serotonin and alcohol intake, abuse, and dependence: findings of animal studies. Biol Psychiatry 1994;36:395-421.
170. LeMarquand D, Pihl RO, Benkelfat C. Serotonin and alcohol intake, abuse and dependence: Clinical evidence. Biol Psychiatry 1994;36:326-37.
171. Yoshimoto K, McBride WJ, Lumeng L, Li TK. Ethanol enhances the release of dopamine and serotonin in the nucleus accumbens of HAD and LAD lines of rats. Alcohol Clin Exp Res 1992;16:781-5.
172. 2 receptors in the mianserin-induced prevention of anxiogenic behaviors occurring during ethanol withdrawal. Alcohol Clin Exp Res 1993;17:411-7.
173. Matsumoto I, Leah J, Shanley B, Wilce P. Immediate early gene expression in the rat brain during ethanol withdrawal. Mol Cell Neurosci 1993;4:485-91.
174. Beckman AM, Matsumoto I, Wilce PA. AP-1 and egr DNA-binding activities are increased in rat brain during ethanol withdrawal. J Neurochem 1997;69:306-14.
175. B receptors have a role in causing behavioural hyperexcitability, both during ethanol withdrawal and in naive mice. Psychopharmacology 1995;117:232-9.
176. Koob GF, Roberts AJ, Schulteis G, Parsons LH, Heyser CJ, Hyytia P, Merlo-Pich E, Weiss F. Neurocircuitry targets in ethanol reward and dependence. Alcohol Clin Exp Res 1998; 22:3-9.
177. 1B serotonin receptors. Nat Genet 1996;14:98-101.
178. Miyakawa T, Yagi T, Kitazawa H, Yasuda M, Kawai N, Tsuboi K, Niki H. Fyn-kinase as a determinant of ethanol sensitivity: relation to NMDA-receptor function. Science 1997;278: 698-702.
179. Yagi T, Aizawa S, Tokunaga T, Shigetani Y, Takeda N, Ikawa Y. A role for Fyn tyrosine kinase in the suckling behavior of neonatal mice. Nature 1993;366:742-5.
180. El-Ghundi M, George SR, Drago J, Fletcher PJ, Fan T, Nguyen T, Liu C, Sibley DR, Westphal H, O'Dowd BF. Disruption of dopamine D1 receptor gene expression attenuates alcohol-seeking behavior. Eur J Pharmacol 1998;353:149-58.
181. DiChiara G, North RA. Neurobiology of opiate abuse. Trends Pharmacol Sci 1992;13:185-192.
182. Mansour A, Fox CA, Akil H, Watson SJ. Opioid-receptor mRNA expression in the rat CNS: anatomical and functional implications. Trends Neurosci 1995;18:22-9.
183. Goldstein A, Naidu A. Multiple opioid receptors: ligand selectivity profiles and binding site signatures. Mol Pharmacol 1989;36:265-72.
184. Smart D, Lambert DG. The stimulatory effects of opioids and their possible role in the development of tolerance. Trends Pharmacol Sci 1996;17:264-9.
185. Lazaurs LH, Bryant SD, Salvadori S, Attila M, Sargent Jones L. Opioid infidelity: novel opioid peptides with dual high affinity for delta and mu receptors. Trends Neurosci 1996;19:31-5.
186. Esposito R, Kornetsky C. Morphine lowering of self-stimulation threshold: lack of tolerance with long-term administration. Science 1977;195:189-91.
187. Mucha RF, Iversen SD. Reinforcing properties of morphine and naloxone revealed by conditioned place preferences: a procedural examination. Psychopharmacology 1984;82:241-7.
188. Spanagel R, Shippenberg TS. Modulation of morphine-induced sensitisation by endogenous kappa opioid systems in the rat. Neurosci Lett 1993;153:232-6.
189. DiChiara G, Imperato A. Opposite effects of mu and kappa opiate agonists on dopamine release in the nucleus accumbens and in the dorsal caudate of freely moving rats. J Pharmacol Exp Ther 1988;244:1067-80.
190. Pontieri FE, Tanda G, DiChiara G. Intravenous cocaine, morphine, and amphetamine preferentially increase extracellular dopamine in the "shell" as compared with the "core" of the rat nucleus accumbens. Proc Natl Acad Sci USA 1995;92: 12304-8.
191. Johnson SW, North RA. Opioids excite dopamine neurons by hyperpolarization of local interneurons. J Neurosci 1992;12: 483-8.
192. 2 dopamine receptors in the nucleus accumbens in the opiate withdrawal syndrome. Nature 1994;371:155-9.
193. Bonci A, Williams JT. A common mechanism mediates long-term changes in synaptic transmission after chronic cocaine and morphine. Neuron 1996;16:631-9.
194. Smith CUM. Elements of molecular neurobiology. New York: Wiley; 1996.
195. Christie MJ, Williams JT, Osborne PB, Bellchambers CE. Where is the locus in opioid withdrawal? Trends Pharmacol Sci 1997; 18:134-40.
196. Ozaita A, Escriba PV, Ventayol P, Murga C, Mayor F, Garcia-Sevilla JA. Regulation of G protein-coupled receptor kinase 2 in brains of opiate-treated rats and human opiate addicts. J Neurochem 1998;70:1249-57.
197. Sklair-Tavron L, Shi W-X, Lane SB, Harris HW, Bunney BS, Nestler EJ. Chronic morphine induces visible changes in the morphology of mesolimbic dopamine neurons. Proc Natl Acad Sci USA 1996;93:11202-7.
198. Nylander I, Vlaskovska M, Terenius L. Brain dynorphin and enkephalin systems in Fischer and Lewis rats: effects of morphine tolerance and withdrawal.
199. Tjon GHK, Voorn P, Vanderschuren LJMJ, DeVries TJ, Michiels NH, Jonker AJ, Klop H, Nestby P, Mulder AH, Schoffelmeer AN. Delayed occurrence of enhanced striatal preprodynorphin gene expression in behaviorally sensitized rats: differential long-term effects of intermittent and chronic morphine administration. Neuroscience 1997;76:167-76.
200. Beitner-Johnson D, Guitart Z, Nestler EJ. Dopaminergic brain reward regions of Lewis and Fischer rats display different levels of tyrosine hydroxylase and other morphine- and cocaine-regulated phosphoproteins. Brain Res 1991;561:147-50.
201. Hayward MD, Duman RS, Nestler EJ. Induction of the c-fos proto-oncogene during opiate withdrawal in the locus coeruleus and other regions of rat brain. Brain Res 1990;525: 256-66.
202. Stornetta RL, Norton FE, Guyenet PG. Autonomic areas of rat brain exhibit increased Fos-like immunoreactivity during opiate withdrawal in rats. Brain Res 1993;623:19-28.
203. Maldonado R, Blendy JA, Tzavara E, Gass P, Roques BP, Hanoune J, Schutz G. Reduction of morphine abstinence in mice with a mutation in the gene encoding CREB. Science 1996;273: 657-9.
204. Chrivia JC, Kwok RP, Lamb N, Hagiwara M, Montminy MR, Goodman RH. Phosphorylated CREB binds specifically to the nuclear protein CBP. Nature 1993;365:855-9.
205. Blendy JA, Maldonado R. Genetic analysis of drug addiction: the role of cAMP response element binding protein. J Mol Med 1998;76:104-10.
206. Guitart X, Thompson MA, Mirante CK, Greenberg ME, Nestler EJ. Regulation of cyclic AMP response element-binding protein (CREB) phosphorylation by acute and chronic morphine in the rat locus ceruleus. J Neurochem 1992;58:1168-71.
207. Windell KL, Self DW, Lane SB, Russell DS, Vaidya VA. Regulation of CREB expression: in vivo evidence for a functional role in morphine action in the nucleus accumbens. J Pharmacol Exp Ther 1996;276:306-15.
208. Nguyen TV, Kosofsky BE, Birnbaum R. Differential expression of c-Fos and zif268 in rat striatum after haloperidol, clozapine, and amphetamine. Proc Natl Acad Sci USA 1992;89: 4270-4274.
209. Konradi C, Cole RL, Heckers S, Hyman SE. Amphetamine regulates gene expression in rat striatum via transcription factor CREB. J Neurosci 1994;14:4270-4.
210. Russell DS, Windell KL, Nestler EJ. Antisense oligonucleotides: new tools for the study of brain function. Neuroscientist 1996;2: 79-82.
211. Matthes HWD, Maldonado R, Simonin F, Valverde O, Slowe S, Kitchen I, Befort K, Dierich A, LeMeur M, Dolle P, Tzavara E, Hanoune J, Roques BP, Kieffer BL. Loss of morphine-induced analgesia, reward effect and withdrawal symptoms in mice lacking the μ-opioid-receptor gene. Nature 1996;383:819-23.
212. 2 receptors. Nature 1997;388:586-9.
213. Kruger L, Saporta S, Swanson LW. Photographic atlas of the rat brain. New York: Cambridge Press, 1995.